Fredun [FREDUN] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison

Fredun Pharmaceuticals Ltd.

BSE
Loading...

Sun Pharma Advanced Research Company Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Fredun Pharmaceuticals Ltd. wins in 15 metrics, Sun Pharma Advanced Research Company Ltd. wins in 3 metrics, with 0 ties. Fredun Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Fredun Pharmaceuticals Ltd. Sun Pharma Advanced Research Company Ltd. Better
P/E Ratio (TTM) 29.83 -13.65 Fredun Pharmaceuticals Ltd.
Price-to-Book Ratio 6.26 -13.55 Fredun Pharmaceuticals Ltd.
Debt-to-Equity Ratio 108.78 -1.21 Fredun Pharmaceuticals Ltd.
PEG Ratio 0.31 -11.15 Fredun Pharmaceuticals Ltd.
EV/EBITDA 13.98 -22.27 Fredun Pharmaceuticals Ltd.
Profit Margin (TTM) 5.53% -53.22% Fredun Pharmaceuticals Ltd.
Operating Margin (TTM) 15.26% -700.71% Fredun Pharmaceuticals Ltd.
EBITDA Margin (TTM) 15.26% N/A N/A
Return on Equity 13.96% 157.88% Sun Pharma Advanced Research Company Ltd.
Return on Assets (TTM) 4.05% -102.08% Fredun Pharmaceuticals Ltd.
Free Cash Flow (TTM) $-351.69M $-3.71B Fredun Pharmaceuticals Ltd.
Dividend Yield 0.09% N/A N/A
1-Year Return 183.86% 34.88% Fredun Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 1.93 87.98 Fredun Pharmaceuticals Ltd.
Enterprise Value $11.27B $50.87B Sun Pharma Advanced Research Company Ltd.
EV/Revenue Ratio 1.91 95.73 Fredun Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 28.72% -59.53% Fredun Pharmaceuticals Ltd.
Revenue per Share (TTM) $1,273 $2 Fredun Pharmaceuticals Ltd.
Earnings per Share (Diluted) $69.90 $-8.25 Fredun Pharmaceuticals Ltd.
Beta (Stock Volatility) 0.46 0.19 Sun Pharma Advanced Research Company Ltd.

Fredun Pharmaceuticals Ltd. vs Sun Pharma Advanced Research Company Ltd. Stock Performance Analysis

Loading Price Chart...

FREDUN
SPARC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Fredun Pharmaceuticals Ltd.0.17%0.73%-2.19%43.43%39.40%50.67%
Sun Pharma Advanced Research Company Ltd.2.36%12.49%39.95%100.62%67.89%69.61%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Fredun Pharmaceuticals Ltd.183.86%158.56%447.18%11,453.75%18,386.00%18,386.00%
Sun Pharma Advanced Research Company Ltd.34.88%14.54%-3.55%-20.47%148.26%-23.02%

Performance & Financial Health Analysis: Fredun Pharmaceuticals Ltd. vs Sun Pharma Advanced Research Company Ltd.

MetricFREDUNSPARC
Market Information
Market Cap i₹11.55B₹46.75B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i11,2592,401,062
90 Day Avg. Volume i9,3012,083,443
Last Close₹2,314.65₹229.03
52 Week Range₹791.00 - ₹2,620.00₹108.00 - ₹248.75
% from 52W High-11.65%-7.93%
All-Time High₹2,620.00 (May 25, 2026)₹875.00 (Apr 24, 2006)
% from All-Time High-11.65%-73.83%
Growth Metrics
Quarterly Revenue Growth0.57%-0.43%
Quarterly Earnings Growth0.97%-0.43%
Financial Health
Profit Margin (TTM) i0.06%-0.53%
Operating Margin (TTM) i0.15%-7.01%
Return on Equity (TTM) i0.14%1.58%
Debt to Equity (MRQ) i108.78-1.21
Cash & Liquidity
Book Value per Share (MRQ)₹333.11₹-10.63
Cash per Share (MRQ)₹18.49₹0.03
Operating Cash Flow (TTM) i₹-1,140,997,000₹-3,484,287,000
Levered Free Cash Flow (TTM) i₹197.39M₹-3,425,094,000
Dividends
Last 12-Month Dividend Yield i0.09%N/A
Last 12-Month Dividend i₹0.70N/A

Valuation & Enterprise Metrics Analysis: Fredun Pharmaceuticals Ltd. vs Sun Pharma Advanced Research Company Ltd.

MetricFREDUN (Apr 24, 2026)SPARC (Apr 22, 2026)
Price Ratios
P/E Ratio (TTM) i29.83-13.65
Forward P/E iN/A2.60
PEG Ratio i0.31-11.15
Price to Sales (TTM) i1.9387.98
Price to Book (MRQ) i6.26-13.55
Market Capitalization
Market Capitalization i₹11.55B₹46.75B
Enterprise Value i₹11.27B₹50.87B
Enterprise Value Metrics
Enterprise to Revenue i1.9195.73
Enterprise to EBITDA i13.98-22.27
Risk & Other Metrics
Beta i0.460.19
Book Value per Share (MRQ) i₹333.11₹-10.63

Financial Statements Comparison: Fredun Pharmaceuticals Ltd. vs Sun Pharma Advanced Research Company Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricFREDUN (2025)SPARC (2025)
Revenue/Sales i4.52B717.66M
Cost of Goods Sold i3.45B1.10B
COGS % of Revenue i76.5%153.2%
Gross Profit i1.06B-381.94M
Gross Margin i23.5%-53.2%
Research & Development i49.76MN/A
Operating Income (EBIT) i475.31M-3.34B
Operating Margin i10.5%-465.5%
EBITDA i530.69M-3.23B
EBITDA Margin i11.7%-450.0%
Pre-Tax Income i274.94M-3.43B
Pre-Tax Income % of Revenue i6.1%-477.6%
Income Tax i77.54M-2.72M
Income Tax % of Revenue i1.7%-0.4%
Net Income (Profit) i197.39M-3.43B
Profit Margin i4.4%-477.3%

Balance Sheet & Liquidity Metrics

MetricFREDUN (2025)SPARC (2025)
Cash & Equivalents i6.37M19.64M
Total Current Assets i4.28B261.97M
Total Current Assets % of Revenue i94.7%36.5%
Total Current Liabilities i3.28B3.74B
Total Current Liabilities % of Revenue i72.6%521.5%
Long-Term Debt i96.13M1.07B
Long-Term Debt % of Revenue i2.1%149.0%
Total Shareholders Equity i1.41B-2.17B
Retained Earnings i628.39M-23.22B
Retained Earnings % of Revenue i13.9%-3,235.0%
Property, Plant & Equipment i95.24M178.02M

Cash Flow Statement Comparison

MetricFREDUN (2025)SPARC (2025)
Operating Cash Flow i-1.14B-3.48B
Operating Cash Flow % of Revenue i-25.3%-485.5%
Capital Expenditures i-59.94M-97.45M
Free Cash Flow i-351.69M-3.71B
FCF Margin i-7.8%-516.4%
Debt Repayment iN/A-3.69B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricFREDUNSPARC
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i5.47M324.52M
Float Shares i534,24191.32M
% Held by Insiders i53.36%72.96%
% Held by Institutions i0.00%2.56%
% Held by Public i46.64%24.48%

Dividend Analysis & Yield Comparison: Fredun Pharmaceuticals Ltd. vs Sun Pharma Advanced Research Company Ltd.

MetricFREDUNSPARC
Last 12-Month Dividend i₹0.70N/A
Last 12-Month Dividend Yield i0.09%N/A
3-Year Avg Annual Dividend i₹0.70N/A
3-Year Avg Dividend Yield i0.08%N/A
3-Year Total Dividends i₹2.10N/A
Ex-Dividend DateSep 23, 2024N/A